James Andry
Family Medicine · Bloomington, INNPI 1447255369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $583,559 of the $714,969 with a category attached, or 81.6%. 45 manufacturers reported payments, led by Lilly USA, LLC at 54.7% of the total. Reporting peaked in 2022 at $157,908 and has fallen 59.7% since, to $63,710 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,337 payments — averaging $534.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$391K
- Novo Nordisk$227K
- Amgen$90K
- Eli Lilly$2K
- AbbVie$982
- AstraZeneca$650
- plus $3K from 39 others
What the payments were for
- Consulting fees$6,5381%
- Speaking & faculty fees$583,55982%
- Travel & lodging$105,64915%
- Food & beverage$19,1983%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$714,969 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 155 | $191,292 |
| TrulicityDulaglutide | 27 | $45,718 |
| OzempicSemaglutide | 30 | $29,598 |
| EliquisApixaban | 27 | $22,415 |
| JardianceEmpagliflozin | 13 | $16,094 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $12,288 |
| TradjentaLinagliptin | 14 | $11,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,767 |
| Testosterone Cypionate | 48 | $4,059 |
| ProgesteroneProgesterone, Micronized | 73 | $3,151 |
| Estradiol (Twice Weekly)Estradiol | 34 | $2,845 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $2,363 |
| ValacyclovirValacyclovir Hcl | 31 | $1,715 |
| Liothyronine Sodium | 29 | $1,599 |
| Duloxetine Hcl | 53 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $391,092 | $237,010182 claims |
| Novo NordiskOzempic | $227,193 | $29,59830 claims |
| Boehringer IngelheimJardiance, Tradjenta | $97 | $27,42627 claims |
| PfizerEliquis | $109 | $22,41527 claims |
| GSKTrelegy Ellipta | $73 | $7,76712 claims |
| AbbVieSynthroid, Armour Thyroid | $982 | $2,11232 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $32 | $91614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Bloomington
- Michael PorvaznikBloomington$18K
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.